Iqvia Holdings Inc IQV

$271.11 -3.42 (-1.25%)

Valuation

Market cap
45,242,544,000
Revenue TTM
$16,310,000,000
Net income TTM
$1,360,000,000
P/E (trailing)
23.76
P/E (forward)
23.86
Profit margin
8.34%
Debt to equity
2.37

Trading

Volume
1,041,121
Avg volume
1,472,216
Day's range
$266.23 – $277.44
Shares out
164,800,000
Stochastic %K
65%
Beta
1.16
Analysts
Strong Buy
Price target
$311.00

Price

Company profile

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud...

Show more

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

Industry
Diagnostics & Research
Sector
Healthcare
Phone
919 998 2000
Website
https://www.iqvia.com
Address
2400 Ellis Road, Durham, United States

Latest news

Stocktwits

GTA_Terminal Nov 7, 7:46 AM
Dark pool check on $IQV: what traded off the exchanges this session. The stock moved +2.6% on the day, so this wasn't happening in a quiet tape. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=IQV&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=IQV Read the full article for the full details: https://globaltradersacademy.com/articles/dark-pool-check-iqvia-iqv?utm_source=stocktwits&utm_medium=social
0 replies
Dr_Stoxx Oct 29, 2:18 PM
The diagnostics space has been hot hot hot. We bankeda nice win in $NTRA in the Live Trading Room. Had $ILMN unofficially (ER tonight). $IQV also good among others:
0 replies
TheTradingAnalyst Oct 29, 6:16 AM
$IQV with a bullish setup... $SPX $SPY $QQQ $VIX Nice setup. Great opportunity to participate in the next up leg. Good luck. Real-time alerts at https://thetradinganalyst.com
0 replies
AXLFI_HQ Oct 28, 11:29 PM
The most recent Buybacks + Momentum signal on $IQV triggered on 2026-10-27. The expected return for the selected horizon is +5.84% with a historical profit probability of +58.09%. Learn more: https://axlfi.com/factors/stock/IQV/fund_buyback_momentum/daily?pass=eyJrIjoibGluayIsImUiOjE3OTM0MDI5NDF9.KmsI9v6Eo-uYn6MLFmJoDQ
0 replies
SainteurNews Oct 28, 1:14 AM
$IQV Clinical trials keep the lights on. IQVIA's Q3 revenue rose 8% to $4.43B, R&D Solutions bookings hit $3.2B (up 15%), and it raised full-year guidance with an investor day set for Dec 1.
0 replies
AXLFI_HQ Oct 28, 12:20 AM
The most recent Buybacks + Momentum signal on $IQV triggered on 2026-10-27. The expected return for the selected horizon is +5.84% with a historical profit probability of +58.09%. Learn more: https://axlfi.com/factors/stock/IQV/fund_buyback_momentum/daily?pass=eyJrIjoibGluayIsImUiOjE3OTMzMTk2Mjh9.kemJdS0wFuB4fQ_EbiRYoQ
0 replies
KryptonResearch14 Oct 27, 7:37 PM
$IQV Q3 adjusted EPS was 3.34 dollars, up 11.3% and ahead of the 3.24 dollars expected, on revenue of 4.43 billion dollars, up 8%. Management said revenue, EBITDA and EPS all came in above the high end of its own expectations. The bookings number is the one that caught my eye. Net new bookings were 3.2 billion dollars, up 15%, a 1.2x book to bill, and the strongest quarterly clinical bookings since 2022. Contracted backlog is 32.6 billion dollars, even after scrubbing 2.1 billion dollars of inactive trials out of it. Full year guidance went up on all three lines, adjusted EPS now 12.90 to 13.00 dollars.
0 replies
shoc24 Oct 27, 5:42 PM
$IQV Reported today: EPS of $3.34 vs. $3.26 expected (+2.5%, beat). Revenue of $4.43B vs. $4.37B expected (+1.4%, beat). I used Stock Meadow’s earnings dashboard to review the results.
0 replies